Drugs / Eltrekibart
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07545590 | Apr → Aug 2026 overdue | — | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT04653168 | Dec 2020 → May 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02896868 | Nov 2016 → Mar 2019 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02148627 | Jun 2014 → Feb 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06598943 | Oct 2024 → Dec 2027 expected | ulcerative colitis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT06046729 | Oct 2023 → Sep 2025 overdue | hidradenitis suppurativa | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04493502 | Aug 2020 → Mar 2022 | hidradenitis suppurativa | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eltrekibart | “A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa.” PMID 41061970 ↗ Oct 2025 |
| Known as | LY3041658 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04653168 ↗ |
| Action | Inhibit | “Neutralizing CXC motif chemokine receptors 1 and 2 ligands offer a promising HS treatment strategy.” PMID 41061970 ↗ Oct 2025 |
| Modality | Monoclonal antibody | “a novel septa-specific monoclonal antibody to CXCR1/2 ligands” PMID 41061970 ↗ Oct 2025 |
| Route | Subcutaneous | “Administered SC” NCT02148627 ↗ |